title: Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction.
abstract: α-Synuclein (αSyn) aggregation and mitochondrial dysfunction both contribute to the pathogenesis of Parkinson disease (PD). Although recent studies have suggested that mitochondrial association of αSyn may disrupt mitochondrial function, it is unclear what aggregation state of αSyn is most damaging to mitochondria and what conditions promote or inhibit the effect of toxic αSyn species. Because the neuronal populations most vulnerable in PD are characterized by large cytosolic Ca(2+) oscillations that burden mitochondria, we examined mitochondrial Ca(2+) stress in an in vitro system comprising isolated mitochondria and purified recombinant human αSyn in various aggregation states. Using fluorimetry to simultaneously measure four mitochondrial parameters, we observed that soluble, prefibrillar αSyn oligomers, but not monomeric or fibrillar αSyn, decreased the retention time of exogenously added Ca(2+), promoted Ca(2+)-induced mitochondrial swelling and depolarization, and accelerated cytochrome c release. Inhibition of the permeability transition pore rescued these αSyn-induced changes in mitochondrial parameters. Interestingly, the mitotoxic effects of αSyn were specifically dependent upon both electron flow through complex I and mitochondrial uptake of exogenous Ca(2+). Our results suggest that soluble prefibrillar αSyn oligomers recapitulate several mitochondrial phenotypes previously observed in animal and cell models of PD: complex I dysfunction, altered membrane potential, disrupted Ca(2+) homeostasis, and enhanced cytochrome c release. These data reveal how the association of oligomeric αSyn with mitochondria can be detrimental to the function of cells with high Ca(2+)-handling requirements.
authors.affiliation: From the Center for Neurologic Diseases, Department of Neurology, and.
authors.forename: Eric S
authors.initials: ES
authors.lastname: Luth
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
authors.forename: Irina G
authors.initials: IG
authors.lastname: Stavrovskaya
authors.affiliation: From the Center for Neurologic Diseases, Department of Neurology, and.
authors.forename: Tim
authors.initials: T
authors.lastname: Bartels
authors.affiliation: Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
authors.forename: Bruce S
authors.initials: BS
authors.lastname: Kristal
authors.affiliation: From the Center for Neurologic Diseases, Department of Neurology, and dselkoe@rics.bwh.harvard.edu.
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Selkoe
mesh_terms: D000818:Animals; D052160:Benzothiazoles; D001704:Biopolymers / Q000737:chemistry / Q000502:physiology*; D002118:Calcium / Q000502:physiology*; D042967:Electron Transport Complex I / Q000378:metabolism*; D006801:Humans; D053078:Membrane Potential, Mitochondrial; D051379:Mice; D008928:Mitochondria / Q000502:physiology*; D013844:Thiazoles / Q000378:metabolism; D051844:alpha-Synuclein / Q000737:chemistry / Q000502:physiology*
chemical_list: D052160:Benzothiazoles; D001704:Biopolymers; D013844:Thiazoles; D051844:alpha-Synuclein; C009462:thioflavin T; D042967:Electron Transport Complex I; D002118:Calcium
keywords: Complex I; Electron Transport System (ETS); Mitochondria; Mitochondrial Permeability Transition (MPT); Parkinson Disease; Protein Aggregation; alpha-Synuclein